Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Large Decline in Short Interest

Fresenius SE & Co. (OTCMKTS:FSNUY) was the target of a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 32,056 shares, a decline of 96.9% from the August 15th total of 1,029,832 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 141,927 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy”.

Fresenius SE & Co. Trading Up 0.6%

Shares of FSNUY stock traded up $0.08 during trading hours on Thursday, hitting $13.00. 70,269 shares of the company were exchanged, compared to its average volume of 150,275. The firm has a market cap of $29.29 billion, a P/E ratio of 16.46 and a beta of 0.62. Fresenius SE & Co. has a fifty-two week low of $10.33 and a fifty-two week high of $33.93. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.98 and a current ratio of 1.27. The company has a 50 day simple moving average of $12.92 and a two-hundred day simple moving average of $12.53.

Fresenius SE & Co. (OTCMKTS:FSNUY) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.33%. The company had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. Equities analysts anticipate that Fresenius SE & Co. will post 1.08 EPS for the current year.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a Germany-based global health care company headquartered in Bad Homburg. The company develops and provides products and services for hospitals, outpatient care, and patients with chronic or complex medical conditions.

Its principal operating businesses are Fresenius Kabi and Fresenius Helios. Fresenius Kabi supplies medicines, clinical nutrition products, infusion and transfusion technologies, and related devices and services. Fresenius Helios operates hospitals and outpatient facilities, primarily in Germany and Spain, providing a broad range of medical and surgical care.

Fresenius traces its origins to a pharmacy established by the Fresenius family in Frankfurt in the 15th century and has evolved into an international health care group serving markets across Europe, North America, Latin America, Asia, and other regions.